Electroporation enhances radiation and doxorubicin-induced toxicity in solid tumor in vivo.
Treatment of cancer patients is subject to limitations in radiotherapy and chemotherapy. This necessitates development of new protocols, and the present work reports on the effects of a combination of local electroporation with ionizing radiation and/or anticancer drug doxorubicin hydrochloride (DOX) on subcutaneous solid tumor murine fibrosarcoma. Localized treatment of fibrosarcoma tumor, grown in right hind leg of Swiss mice, has been carried out using DOX (0.6 mg/kg body weight), radiation (Co 60 gamma-rays, dose rate 0.37 Gy/min) and electroporation (1 kV/cm, 200 micros, 8 pulses per burst, 10 bursts) individually or in combinations. Measurements of the tumor growth kinetics after treatment with combinations have revealed significant growth delay. The treatment groups, (i) radiation and electroporation, (ii) DOX and electroporation, and (iii) radiation, DOX and electroporation, have yielded tumor growth delays (TGDs) of 1.22, 1.5, and 1.73 days, respectively, compared to control with the tumor volumes being 53%, 57%, and 49% that of control on the final day of observation. These results suggest that the antitumor effects of a moderate dose of gamma radiation and low concentration of DOX can be significantly enhanced by combination with electroporation.
Shil
Pratip
P
Biophysics Laboratory, Department of Physics, University of Pune, Pune 411007 India. pratip@physics.unipune.ernet.in
Kumar
Amit
A
Vidyasagar
Pandit B
PB
Mishra
Kaushala P
KP
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D053672:Electrochemotherapy; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D051379:Mice; D009368:Neoplasm Transplantation; D014677:Pharmaceutical Vehicles; D012513:Sarcoma, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy
D000903:Antibiotics, Antineoplastic; D014677:Pharmaceutical Vehicles; D004317:Doxorubicin